SEND NEWS ARTICLE TO FRIEND
To Email:
From Email:
News Headline
Imperial College Innovations Limited Portfolio Company Circassia Limited Achieves Key Phase II Clinical Development Milestone with Toleromune T-Cell Vaccine Technology for Treatment of Allergies